TY - JOUR T1 - Apparent Diffusion Coefficent Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. DO - 10.3174/ajnr.A2385 AU - W.B. Pope AU - A. Lai AU - R. Mehta AU - H.J. Kim AU - J. Qiao AU - J.R. Young AU - X. Xue AU - J. Goldin AU - M.S. Brown AU - P.L. Nghiemphu AU - A. Tran AU - T.F. Cloughesy Y1 - 2011/02/16 UR - http://www.ajnr.org/content/early/2011/02/17/ajnr.A2385.abstract N2 - BACKGROUND AND PURPOSE: Currently it is difficult to predict tumor response to anti-angiogenic therapy in individual patients. Our aim was to determine if ADC histogram analysis can stratify progression-free and overall survival in patients with newly diagnosed GBM treated “up-front” (ie, before tumor recurrence) with bevacizumab. MATERIALS AND METHODS: Up-front bevacizumab-treated and control patients (n = 59 and 62, respectively) with newly diagnosed GBM were analyzed by using an ADC histogram approach based on enhancing tumor. Progression-free and overall survival was determined by using Cox proportional HRs and the Kaplan-Meier method with logrank and Wilcoxon tests. RESULTS: For up-front bevacizumab-treated patients, lower ADCL was associated with significantly longer progression-free survival (median, 459 days for ADCL < 1200 versus 315 days for ADCL ≥ 1200 10−6mm2/s; P = .008, logrank test) and trended with longer overall survival (581 versus 429 days, P = .055). ADC values did not stratify progression-free or overall survival for patients in the control group (P = .92 and P = .22, respectively). Tumors with MGMT promoter methylation had lower ADCL values than unmethylated tumors (mean, 1071 versus 1183 10−6mm2/s; P = .01, 2-group t test). CONCLUSIONS: Pretreatment ADC histogram analysis can stratify progression-free survival in bevacizumab-treated patients with newly diagnosed GBM. Lower ADC is associated with tumor MGMT promoter methylation, which may, in part, account for the favorable outcome associated with low ADCL tumors. ER -